Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration. - ARMAVA

.L.S.S. 160 个研究点开始时间: 2009年11月25日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients affected by exudative age-related macular degeneration, patients with age ≥50 years, type of choroidal neovascularization (CNV), classic, minimally classic and occult CNV, location of CNV: subfoveal, juxtafoveal and extrafoveal, size of CNV ≤ 5.4 mm (9 DD), leakage on fluorescein angiography ≥ 50% of the entire CNV area, subretinal fibrosis ≤ 50% CNV area, OCT thickness ≤ 450 ?m, best-corrected visual acuity between 20/100 and 20/320, previous treatment with anti-VEGF, PDT, laser and others, onset of symptom ≤ 30 days before treatment, presence of hemorrhage ≤ 70% of the entire CNV area, CNV associated with serious pigment epithelium detachment, patient with retinal angiomatous proliferation.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Visual acuity ≥ 20/100, neovascular lesion associated with chorioretina-retinal folds, chorioretinal atrophy, tear of retinal pigment epithelium, uncontrolled blood pressure, opacities of the clear refractive media of the eye such as the cornea, anterior chamber, lens and vitreous, abnormalities of coagulation, renal failure, thromboembolic events, stroke, TIA, arrhythmia 6 months before the study start, general surgery planned 3 months the study start, general surgery 2 months before the study start, pregnant woman. women on breast-feeding.

发起方

.L.S.S. 16